Is EXOZ or GLUE more undervalued in 2026?

CirclFi compares eXoZymes Inc. (EXOZ) and Monte Rosa Therapeutics, Inc. (GLUE) using 13 institutional-grade valuation models. EXOZ has a Quality of Company score of 4.5/10 while GLUE scores 5.2/10.

Which is a better buy — EXOZ or GLUE?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do EXOZ and GLUE valuations compare?

EXOZ at $9.85 and GLUE at $19.71 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

EXOZ vs GLUE Valuation Comparison 2026 — Intrinsic Value Analysis

EXOZ

Biological Products, (No Diagnostic Substances)

eXoZymes Inc.

Quality

4.5

out of 10

Value Trap

—

Price

$9.85

Last close

Models

6/13

Active

GLUE

Biological Products, (No Diagnostic Substances)

Monte Rosa Therapeutics, Inc.

Quality

5.2

out of 10

Value Trap

SAFE

Price

$19.71

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	EXOZ Fair Value	EXOZ Upside	GLUE Fair Value	GLUE Upside
Bayesian DCF	Intrinsic	$2.50	-74.6%	$5.96	-69.8%
Earnings Power Value	Intrinsic	—	—	$3.72	-80.2%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$0.29	-97.1%	$4.13	-79.0%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for EXOZ vs GLUE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

EXOZ vs GLUE — Which Stock Is More Undervalued?

GLUE scores higher with a 5.2/10 quality rating vs EXOZ's 4.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing eXoZymes Inc. (EXOZ) and Monte Rosa Therapeutics, Inc. (GLUE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

EXOZ currently trades at $9.85 with a QOC of 4.5/10, while GLUE trades at $19.71 with a QOC of 5.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).